Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Product/R&D News
9/1/2025
Novel iPSC-Derived Neural Cell Therapy Shows Promise in SCI Treatment
9/1/2025
Hengrui Seeks NMPA Approval for New Dual-Receptor Obesity Drug HRS9531
8/30/2025
CMS Subsidiary Gets Approval to Launch Clinical Trials of Povorctinib
8/29/2025
D3 Bio's D3S-001 Receives FDA Breakthru Therapy and Orphan Drug Design...
8/29/2025
Boehringer's Zongertinib Gains Conditional Approval in China
8/29/2025
Hengrui's SHR2554 Receives Conditional NMPA Approval
8/29/2025
Akeso Advances First Bispecific ADC Into Clinical Stage With First Pat...
8/26/2025
Akeso's Ivonescimab Secures First Demonstrated OS Benefit in Lung Can...
8/26/2025
Arnatar Debuts with FDA Designations for Alagille Syndrome Candidate A...
8/26/2025
Akeso's Dual Phase III Victories Highlight Expansion of Non-Oncology T...
8/26/2025
Simcere's Daridorexant Phase III Data Published and Approved in China
8/26/2025
Pregene Secures Orphan Drug Status for Innovative Dual-Target CAR-T Th...
8/26/2025
CorrectSequence's CS-101: A Breakthru Base-Editing Therapy Cures First...
8/26/2025
Centergene's SJ02 Approved for Marketing, Advancing Assisted Reproduct...
8/25/2025
HemaCell Receives FDA IND Approval for Megakaryocyte Therapy
8/25/2025
Vivace Therapeutics Secures FDA Orphan Drug Designation for VT3989 in ...
8/22/2025
NMPA Approves AZ/Daiichi Sankyo's Datopotamab Deruxtecan
8/22/2025
Innovent Advances Immuno-Oncology with IBI3026 CTA Acceptance
8/22/2025
Xuanzhu's Dexitinib Gains Approval for ALK-Positive Advanced NSCLC in ...
8/22/2025
NMPA Approves Domestic Hexavalent Rotavirus Vaccine for Children
8/22/2025
CARsgen's Satri-cel Becomes First CAR-T Therapy for Solid Tumors to Re...
8/22/2025
Kintor's KX-826 Tincture Nabs Triumph in Phase II Male AGA Trial
8/21/2025
Anixa Secures First Chinese Patent for Breast Cancer Vaccine Technolog...
8/21/2025
Zelgen Secures FDA IND Approval for Novel Trispecific Cancer Therapy
8/21/2025
Novartis' Vanrafia (atrasentan) Gains Regulatory Nod in China as Secon...
8/21/2025
Nicox Targets U.S. and China Filings After Second Phase III Win for NC...
8/20/2025
Pfizer Advances Pneumococcal Vaccine Development in China with Phase 1...
8/19/2025
Onconic's GERD Drug Jaqbo Advances in China Following Phase 3 Success
8/19/2025
CSPC Pharma Advances in Biosimilars with Dupilumab Injection Approval
8/19/2025
Innovent Presents Phase 2 Study of Tarlatamab in Third-Line ES-SCLC at...
Page:
3
/
20
Total number of articles:
583
:
[First]
[<<]
[1]
[2]
[3]
[4]
[5]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit